Survey on the SARS-CoV-2 serum antibody retention and health condition both before and after the SARS-CoV-2 vaccine introductio
Not Applicable
- Conditions
- severe acute respiratory syndrome coronavirus 2SARS-CoV-2 infectionC000656484
- Registration Number
- JPRN-jRCT1061200057
- Lead Sponsor
- akano Takashi
- Brief Summary
Four weeks after vaccination for COVID-19, SCR 99.9%, SPR 99.9%, and GMT 2685.5 suggesting high immunogenicity.Although a certain percentage of adverse reactions were observed after vaccination for COVID-19, no serious side effect was observed, suggesting safety of vaccination for COVID-19.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 2409
Inclusion Criteria
School staff who wish to be vaccinated against the SARS-CoV-2
School staff who have agreed to participate in this study
Exclusion Criteria
none
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Transition of SARS-CoV-2 serum antibody titer both before and after the SARS-CoV-2 vaccine introduction
- Secondary Outcome Measures
Name Time Method Retention status of SARS-CoV-2 serum antibody before the SARS-CoV-2 vaccine introduction.<br>Health condition after the SARS-CoV-2 vaccine introduction